TABLE 1

¹⁸F-FDG PET Evaluation of Response to Therapy of Carcinoma of Head and Neck

Reference	No. of patients	Therapy	Stage	Time of PET	% Sensitivity	% Specificity
7	6	RT + chemo	III	During Rx	NA	NA
15	47	RT + chemo	II–IV	During Rx	NA*	NA*
19	12	Chemo	III–IV	During Rx	NA	NA
28	12	RT	NS	During or at completion of Rx	NA	NA
8	22^†	RT	NS	Completion of Rx	100	80
	18^‡				86	100
10	22	RT + chemo	II–IV	Completion of Rx	NA	NA
11	44	RT + chemo	III–IV	Completion of Rx	100	93
12	19	Chemo	III–IV	Completion of Rx	NA	NA
13	28	Chemo	III–IV	Completion of Rx	90	83
17	15	RT + chemo	I–IV	Completion of Rx	NA	NA
18	63	RT + chemo	III–IV	Completion of Rx	NA^§	NA^§
21	34	RT	NS	Completion of Rx	NA	NA
25	20	RT	NS	Completion of Rx	87	67
22	23^‖	Chemo	III	Completion of Rx	75	86
	11^¶				50	75
31	15	RT	II–IV	Completion of Rx	NA	NA

↵* Low (<16 μmol/min/100 g) and high (≥16 μmol/min/100 g) ¹⁸F-FDG metabolic rates were associated with complete remission in 96% and 62% and with 5-y survival in 72% and 35%, respectively.
↵^† At 1 mo after completion of RT.
↵^‡ At 4 mo after completion of RT.
↵^§ Patients with high tumor ¹⁸F-FDG uptake (SUV, >5.5 mg/mL) had significantly lower 3-y local control (55% vs. 86%) than did those with low ¹⁸F-FDG uptake (SUV, ≤5 mg/mL).
↵^‖ Patients who had undergone surgical resection.
↵^¶ Patients for whom biopsy specimens of lesion were obtained after chemotherapy.
Chemo = chemotherapy; Rx = therapy; NA = not available, but all of these studies showed various degrees of decrease in ¹⁸F-FDG uptake after therapy in patients with favorable therapy responses; NS = not specified.